Skip to content

Prevention and treatment of low-dose naloxone on perioperative opioid-induced hyperalgesia

Prevention and treatment of low-dose naloxone on perioperative opioid-induced hyperalgesia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006651
Enrollment
Unknown
Registered
2015-06-25
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperalgesia

Interventions

Control group 1:Induction of anesthesia: Remifentanil, sevoflurane, cisatracurium, Postoperative analgesia with sufentanil, tropisetron
Treatment group 1:Induction of anesthesia: Remifentanil, sevoflurane, cisatracurium, low-dose naloxone, Postoperative analgesia with sufentanil, tropisetron, low-dose naloxone
Control group 2:Induction of anesthesia: Remifentanil, sevoflurane, cisatracurium, Maintenance of anesthesia: Remifentanil, sevoflurane, Postoperative analgesia with fentanil, tropisetron
Treatment group 2:Induction of anesthesia: Remifentanil, sevoflurane, cisatracurium, low-dose naloxone, Maintenance of anesthesia: Remifentanil, sevoflurane, low-dose naloxone, Postoperative analgesia
Control group 3:After the success of subarachnoid block, continuous intravenous infusion of remifentanil. Postoperative analgesia with sufentanil, tropisetron.
Treatment group 3:After the success of subarachnoid block, continuous intravenous infusion of remifentanil and low-dose naloxone. Postoperative analgesia with sufentanil, tropisetron, low-dose naloxon

Sponsors

Beijing Military General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 50 Years

Inclusion criteria

Inclusion criteria: Cholecystectomy patients and lower extremity fracture patients aged 18 to 65 years old, hydronephrosis (and hernia) pediatric patients aged 5 to 12 years old.

Exclusion criteria

Exclusion criteria: 1. Long-term use of analgesic drugs, sedatives, antidepressants and psychotropic drugs; 2. patients suffering from severe heart disease, chronic pain, drug addicts, drug allergies; 3. patients who do not agree with experiment.

Design outcomes

Primary

MeasureTime frame
pain threshold;Pain Visual analog scale;Opioid consumption;Opioid side effects;

Countries

China

Contacts

Public ContactYa-qun Ma
bjmzk@sina.com+86 13381138327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026